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Abstract
Respiratory syncytial virus (RSV) is the most common cause of acute lower 
respiratory tract infection in young children worldwide, accounting for an estimated 33.8 
million cases of respiratory disease, over 3 million of which require hospitalization, and 
between 66,000 and 199,000 deaths in this susceptible population. Additionally, severe 
RSV infection early in life is associated with an increased risk of wheeze and other 
airway disorders later in life. Despite this, there is currently no vaccine or economically 
reasonable prophylactic regimen to prevent infection. While disease is typically more 
severe in infancy RSV can infect throughout the lifespan repeatedly as the body does 
not develop protective immunity during primary or subsequent infection. The 
mechanisms behind this incomplete immunity are unclear.
RSV has been reported to infect numerous extra-epithelial cell types. 
Interestingly, viral infection in human mesenchymal stem cells (MSCs) has been 
reported, but the consequences are poorly understood. MSCs are an immune 
regulatory cell population present in nearly every organ including the nasal mucosa and 
the lung. They play a role in regulating immune responses and mediating tissue repair. 
In the following studies we sought to determine whether RSV infection of MSCs 
enhances their immune regulatory functions and contributes to RSV-associated lung 
disease.
vii
RSV was shown to replicate in human MSCs by fluorescence microscopy, 
plaque assay, and expression of RSV transcripts. RSV-infected MSCs showed 
differentially altered expression of cytokines and chemokines such as IL-1β, IL-6, IL-8 
and SDF-1 compared to normal human bronchial epithelial cells. Notably, RSV-infected 
MSCs exhibited significantly increased expression of IFN-β (~100-fold) and 
indoleamine-2,3-dioxygenase (IDO) (~70-fold) compared with mock-infected MSCs. IDO 
was identified in cytosolic protein of infected cells by Western blots and enzymatic 
activity was detected by tryptophan catabolism assay. Treatment of PBMCs with culture 
supernatants from RSV-infected MSCs reduced their proliferation in a dose dependent 
manner. This effect on PBMC activation was reversed by treatment of MSCs with the 
IDO inhibitors 1-methyltryptophan and vitamin K3 during RSV infection.
We also demonstrated the pathway leading to IDO expression in RSV infected 
MSCs. Neutralizing IFN-β prevented IDO expression and activity indicating its role as a 
viral response factor perhaps “high jacked” by the virus in immune escape. Treatment of 
MSCs with an endosomal TLR, but not a RIG-I, inhibitor prevented IFN-β and IDO 
expression. Additionally, TLR3/dsRNA complex inhibitor was able to block IFN-β 
stimulation, while a TLR7/8/9 inhibitory ODN did not, suggesting that endosomal TLR3 
detection of RSV dsRNA was leading to IFN-β and IDO expression. Together, these 
findings indicate that RSV infection of MSCs triggers their immune regulatory function 
via TLR3 recognition of dsRNA, upregulating IFN-β expression and IDO activity, 
ultimately affecting immune cell proliferation. This finding may account for the lack of 
protective RSV immunity and consequent repeated infections throughout one’s lifetime.
1Chapter 1: Introduction and Background
1.1 Significance of respiratory syncytial virus
RSV infections occur in nearly all children by the age of 3 years and reinfection 
even within the same season is common. This is due to the lack of development of a 
protective immune response including neutralizing antibodies to the virus [1], and 
neonatal infection may occur even in the presence of maternal antibodies in the serum 
specific to RSV [2]. At present no approved vaccine exists and the only available 
prophylaxis is the monthly injection of a costly monoclonal antibody as a passive 
immunotherapy, which is limited in use to only those infants at high risk of respiratory 
distress; including those that are immunocompromised or born with congenital heart 
defects [3, 4]. This is due to the fact that while RSV infections generally manifest as a 
mild cold in healthy individuals disease can be more severe in at risk neonates and 
infants.  Similarly, RSV can cause serious disease in susceptible immunocompromised 
adult populations including transplant recipients, cancer patients, persons with AIDS 
and the elderly; leading to lower respiratory infections including bronchiolitis and 
pneumonia [5, 6]. Unlike the neonatal and infant populations there is no approved or 
economical prophylaxis for these at risk adult populations.
In the United States RSV is estimated to be the cause of 24% of all lower 
respiratory tract infection (LRTI)-associated hospitalizations of children less than 5 
2years old, accounting for between 132,000-172,000 hospitalizations every year [7]. 
Populations at an increased risk of viral and bacterial infections such as preterm infants 
and those with congenital respiratory or circulatory disorders are especially susceptible 
to severe RSV-associated LRTI [8-10]. One study indicated that between 40% and 60% 
of premature infants that were hospitalized for LRTI were suffering from RSV-related 
illness [11]. Studies have shown that infants who develop severe RSV-associated LRTI 
have decreased lung function and increased airway resistance [12]. Additionally, a long-
term outcome study following infants hospitalized for RSV-related LRTI found that these 
infants showed increased airway disease such as asthma and recurrent wheeze as well 
as high serum anti-allergen IgE levels even 18 years after being hospitalized [13].
In addition to the increased risk of infection, preexisting congenital disorders 
have been associated with significantly increased morbidity associated with RSV LRTI 
[14]. Neonatal congenital heart disease (CHD) has been associated with significantly 
higher mortality from RSV LRTI with an alarming 37% mortality rate for neonates born 
with CHD versus 1.5% for those born without heart defects [15]. Also, the length of 
hospitalization and incidence of hospital-acquired RSV infection is higher in CHD 
neonates [8, 16]. Children who suffer from immune suppression, such as those with 
human immunodeficiency virus (HIV) infections, are also at an increased risk of RSV-
associated lung disease. One study found that HIV-infected children had a 92.3% 
incidence rate of RSV-induced pneumonia compared with 68.8% in uninfected children 
[17]. Severe RSV is associated with extended hospital stays and may require costly 
medical interventions such as mechanical ventilation. A study involving infants under 1 
3year old from 1997 to 2000 reported 311,077 hospitalizations resulting from RSV 
bronchiolitis at an estimated cost of $3 billion [18].
Beyond its impact in mortality and morbidity of infants and children, RSV has also 
been shown to be an important pathogen in aged populations, accounting for an 
estimated 30% of respiratory related healthcare visits in individuals over the age of 65 
[5] with a 8% mortality rate [19]. Additionally, reports suggest RSV is responsible for 
between 8.2 and 25.4 hospitalizations per 10,000 patients over the age of 50 [20]. And 
although it is typically considered a pediatric respiratory disease the number of deaths 
annually attributed to RSV is markedly higher in adults over 65 years of age, with a 
mortality rate two-fold higher than the rate in children under 5 [19]. Differences in 
adaptive and innate immune system associated with aging may account for increased 
susceptibility and mortality in aged populations [21].
1.2 Development of vaccines and therapeutics
Despite first being identified in the 1960’s there is currently no approved vaccine 
for RSV. An early vaccination trial using a formalin-inactivated virus failed when the 
treatment was associated with increased disease severity and mortality upon 
subsequent natural infection [22]. The only approved measure to prevent RSV-
associated disease is a passive immune treatment using a monoclonal antibody 
designed to inhibit fusion of the virus to target cells [23]. This antibody, palivizumab, 
also known by the brand name Synagis (MedImmune), is only prescribed to select high-
risk neonates and infants such as those with CHD or chronic lung disease or those born 
prematurely [4, 9, 24], as described previously. Despite being associated with 
decreased hospitalization rates for RSV-associated bronchiolitis and pneumonia cost-
4benefit analyses suggest that it is not viable as a preventative treatment in healthy 
infants, children, or adults or elderly [4, 9, 25].
Other vaccination efforts are currently in development and clinical trials including 
a nanoparticle vaccine composed of an immunogenic fusion protein subunit [26] as well 
as an RNA-interference based vaccine against RSV genes [27-29]. Additionally, an 
alternative neutralizing antibody motavizumab (MED-254, MedImmune) has been 
developed [30-32] but was not approved by the FDA due to lack of evidence that it 
prevented RSV disease better than the current approved treatment and the increased 
risk for adverse events at the injection site.
1.3 RSV structure and genes
Respiratory syncytial virus (RSV) is an enveloped single-stranded negative-
sense RNA virus of the Pneumovirus genus in subfamily pneumovirinae of the 
Paramyxoviridae family. The defining characteristic of Paramyxoviridae viruses is a 
fusion protein F that facilitates viral entry into host cell via membrane fusion. In addition 
to the F protein RSV also displays two other surface glycoproteins in its envelope: the 
small hydrophobic SH protein as well as the major surface glycoprotein G. Variability in 
RSV G protein is used to differentiate human RSV into two subtypes: A and B. Of the 
two, RSV subtype A is more predominant and virulent [33]. 
Structurally, RSV forms a spherical virion between 150 and 300 nm in diameter 
with a lipid bilayer envelope formed during budding from the host cell [34]. Within the 
viral envelope lies a nucleocapsid containing the viral genome as well as proteins 
necessary for viral replication. After attachment, fusion, and uncoating the virus begins 
replication in the cytoplasm of the infected cell. The virus’s RNA genome is just over 
515,000 nucleotides in length and codes for 11 proteins including the two nonstructural 
proteins NS1 and NS2; the nucleoprotein N; a phosphoprotein P; the matrix protein M; 
the three previously mentioned envelope proteins SH, G, and F; transcription factors 
M2-1 and M2-2; and the large polymerase subunit protein L. In a similar fashion to other 
non-segmented negative strand RNA viruses the genome of RSV serves as a template 
for transcription of viral mRNAs and genomic replication. Replication occurs through 
generation of a full-length antigenome, which is used as a template for genomic RNA 
synthesis. Both the genome and antigenome are found in the cell cytosol tightly bound 
to the N protein, which protects them from degradation by host cell ribonuclease activity. 
A polymerase complex made up of the L, P, and M2 proteins facilitate both transcription 
and replication [35]. NS1 and NS2 are not found within the virion nor are they required 
for viral infection or replication, however they have been shown to enhance viral 
infection through regulation of host cell antiviral responses [36-40]. In contrast, 
pathogenesis of RSV is dependent on the function of the G protein [41], which facilitates 
attachment of virus to host cell, and the F protein, which is necessary for fusion of virion 
with the host cell membrane allowing entry. Syncytia formation for which the virus is 
named is dependent on the F protein. Virus transmission from cell to cell may occur by 
either syncytial formation through cell-cell fusion or through viral budding and 
attachment to distal cells.
Mucosal cells of the airway epithelium are considered the chief target of RSV, 
although infections in a number of other cell types have been reported both in vitro and 
in vivo. Several cell surface receptors for RSV have been described: heparin-like 
6glycosaminoglycans [42, 43]; toll-like receptor 4 (TLR4) and CD14 [44]; intercellular 
adhesion molecule-1 (ICAM-1) [45]; and fractalkine receptor (CX3CR1) [46].
Following RSV infection epithelial cells produce proinflammatory cytokines and 
chemokines, which recruit immune cells to the airway. The interaction of RSV with TLR4 
activates the transcription factor NF-κB leading to the transcription of genes responsible 
for the inflammatory response [47, 48]. Other members of the TLR family including the 
endosomal TLR3 and TLR7/8 have also been reported to play role in immune 
responses to RSV [49, 50]. Additionally, virus genome and transcripts are detected 
through other pattern recognition receptors (PRR) such as RIG-I and MDA5 [8, 38], 
which have also been shown to activate host immune responses.
1.4 Epidemiology of RSV
Although RSV infections may occur at any time of year outbreaks typically follow 
a seasonal pattern and despite repeated infections individuals are susceptible to 
reinfection each year. During the 2015-2016 RSV season infections began to increase 
in October 2015 and continued through the New Year until starting to taper off in March 
2016, ending in early May [51]. The exception to the seasonal outbreak pattern in the 
United States is Florida, which has both an earlier onset and later tapering leading to an 
extended RSV season. RSV outbreaks are typically due to one of the two major 
antigenic groups, A or B, which vary in their RSV surface glycoprotein G [41]. Unlike 
some other viruses, such as influenza, which undergo genome rearrangement to modify 
surface antigens and thereby avoid immune detection RSV antigenicity does not vary 
greatly from season to season. Rather than changing the surface proteins it is believed 
that RSV avoids protective immunity by modulating the immune response during an 
7infection such that reinfection is possible even within the same RSV season. 
Understanding the various mechanisms that RSV uses to alter immunity may help 
provide real solutions for the treatment and prevention of RSV infection and reinfection 
and reduce the burden this virus puts on global public health.
1.5 Interactions with the immune system
RSV infections occur repeatedly throughout an individual’s lifetime, suggesting 
that although there is an immune response to the virus it does not provide lasting 
immunity. The 15 kilobase single-stranded genome of RSV codes for eleven proteins; 
Several structural components which make up the nucleocapsid and receptors in the 
envelope as well as two nonstructural genes which are not packaged in the virion. 
These genes, nonstructural protein 1 and 2 (NS1 and NS2), are the most promoter-
proximal genes in the genome meaning they are the earliest and most heavily 
transcribed [36, 37, 52]. NS2 and NS1 have been implicated to regulate a number of 
host cellular processes. RSV NS2 has proteolytic functions and has been shown to be 
involved in regulation of RNA synthesis. Additionally, it antagonizes the interferon 
signaling by interfering with components of JAK-STAT pathway [38, 53, 54]. Similarly 
NS1 has been found to interfere with the STAT1, TRAF3, and IKKε pathways [37, 40, 
55, 56]. Both nonstructural proteins have been found to suppress type I, II, and III 
interferons by both directly binding RIG-I as well as promoting ubiquitin-mediated 
STAT2 degradation by the proteasomal pathway [38, 57-59]. Neither NS1 nor NS2 are 
critical for viral replication [36].
Other viral proteins also play a role in preventing or delaying host cell detection 
and response to infection. The phosphoprotein P and nucleoprotein N protect the viral 
8genome from the host cell and are involved in the creation of inclusion bodies which 
decrease type I interferon [60]. The envelope proteins F and G not only serve as viral 
attachment and fusion mediators but have been found to be secreted and may play a 
role in blocking antibodies that would otherwise bind to and neutralize the virus [61, 62]. 
Additionally, RSV G can bind to CX3CR1, the chemokine receptor, competing with it’s 
ligand fractalkine [63]. G has also been implicated in the stimulation of suppressor of 
cytokine signaling (SOCS) proteins 1 and 2, which in turn regulate interferon responses 
[64]. Surface expression of TLR4 and intercellular adhesion molecule-1 (ICAM-1) is also 
increased by infection with RSV [65, 66].
1.6 Extrapulmonary and extra-epithelial infections
In addition to the epithelial cells of the nasal mucosa and lower respiratory tract 
RSV has been shown to infect a multitude of other cell types. In addition to a number of 
non-respiratory tissues which may be infected in rare cases of severe disease [67] there 
are a number of studies indicating that even during a normal RSV infection non-
epithelial cells may be infected. For example there is evidence that pulmonary 
endothelial cells may also be targets for RSV and infection may increase cell adhesion 
molecules, increasing leukocyte adhesion and extravasation into the lung [66]. 
Additionally, RSV has been found to infect and replicate in a number of cells present at 
the sites of infection including pulmonary macrophages [68, 69] as well as dendritic cells 
[70-72]. Neutrophils, a cell type responsible for mediating rapid innate immune 
responses to pathogens have also been isolated from the blood and bronchial-alveolar 
lavages of RSV infected infants and shown to contain productive, replicating virus [73-
75]. Cells of the stroma have also been found to be a potential target for RSV. Freshly 
9isolated bone marrow-derived MSCs were found to contain transcripts for the 
nucleocapsid N gene and were found highly permissive to RSV in vitro [76]. These 
findings suggest that perhaps a resident stromal cell type such as MSCs in the lung or 
nasal mucosa could be an extra-epithelial target for RSV and contribute to RSV-
mediated regulation of the immune system.
1.7 Mesenchymal stem cells as immune regulatory cells
Mesenchymal stem cells (MSC, also known as multipotent stromal cells) are a 
class of undifferentiated multipotent cells originally isolated from bone marrow [77, 78] 
but have since been identified and isolated from numerous adult tissues including 
adipose tissue, brain, muscle, as well as the airway mucosa [79-82]. Phenotypically 
they are a fibroblast-like plastic-adherent cell characterized by their ability to 
differentiate into adipocytes, chondrocytes, and osteocytes as well as a panel of surface 
markers including CD105, CD90, CD44, and STRO-1. They serve as a readily available 
reservoir of reparative cells for tissue regeneration; able to mobilize, proliferate and 
differentiate into multiple lineages of cells in response to specific signals [83, 84].
In addition to their function in tissue maintenance and repair they have also been 
identified as immune regulatory cells capable of secreting immune modulating factors 
as well as interacting directly with immune and antigen presenting cells [85-89]. Studies 
in allogeneic bone marrow transplantation recipients have found that co-transfusion of 
MSCs with hematopoietic stem cells reduces the incidence and severity of graft-versus-
host disease post-transplantation [85, 90, 91]. MSCs have been found to suppress 
immune responses of many immune cells types including T cells, B cells, natural killer 
cells, granulocytes and dendritic cells. In T cells they have been found to inhibit antigen-
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specific T cell proliferation as well as cytotoxicity in addition to increasing the generation 
of regulatory T cells. MSCs have also been shown to reduce the proliferation of B cells 
in response to mitogen stimulation. They also influence cells of the innate immune 
response, such as neutrophils in which they have been shown to impair respiratory 
burst via IL-6 secretion [92]. 
1.8 Concluding remarks
The following work is designed to investigate and understand the role that may 
MSCs play in RSV infection. To begin this study MSCs were first infected and analyzed 
for permissiveness and productivity of RSV. Then inflammatory and antiviral response 
factors were assayed to investigate the response MSCs had against RSV. Next the 
effect on MSCs in terms of their immune regulatory role was explored and the 
mechanisms behind these responses were investigated. Finally, a comparison of these 
results to a common animal model of RSV, the mouse model, was completed. The 
findings of this study suggest a role for RSV-infected MSCs in RSV immune evasion, 
persistence, and recurrent infections. 
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Chapter 2: Materials and Methods
2.1 Cell and virus lines
Cell lines used in the following experiments included the human epithelial cell line 
HEp-2 (HeLa contaminant, ATCC #CCL-23), the human alveolar epithelial cell line A549 
(ATCC #CCL-185), and the African green monkey kidney epithelial cell line Vero (ATCC 
#CCL-81) which were each purchased from the American Type Culture Collection 
(Manassas, VA), grown in Dulbecco’s modified Eagle’s medium (DMEM) with 5% fetal 
bovine serum (FBS), L-glutamine, and the antibiotics penicillin and streptomycin at 100 
units/ml and 100 μg/ml respectively. Additionally, two sources of human MSC lines were 
used in these experiments: Umbilical cord blood derived MSCs were purchased from 
Vitro Biopharma (Golden, CO) and bone marrow derived MSCs were obtained from the 
Institute for Regenerative Medicine at Scott and White Texas A&M Health Science 
Center (Temple, TX). MSCs were grown in complete MSC media made up of alpha 
minimum essential media (αMEM) supplemented with 16.5% non-heat inactivated FBS, 
Glutamax (Life Technologies, Carlsbad, CA), 100 units/ml penicillin, and 100 μg/ml 
streptomycin. All experiments were performed with MSCs passaged fewer than 10 
times. Normal human bronchial epithelial (NHBE) cells were purchased from Lonza 
(Allendale, NJ) and grown in bronchial epithelial growth medium (BEGM, Lonza). No 
NHBE cells were used beyond passage 5.
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RSV A2 was originally purchased from the ATCC (#VR1302). Recombinant RSV 
A2 expressing green fluorescent protein (rgRSV) was provided by Dr. Mark Peeples 
(Nationwide Children’s Hospital, Columbus, OH). Recombinant RSV A2 expressing 
mKate2 and the F protein of RSV line 19 (rA2-KL19F) was generously provided by Dr. 
Martin Moore (Emory University, Atlanta, GA). All virus infections were performed for 90 
min at 37ºC with virus diluted in Opti-MEM supplemented with 2% FBS. Viral stocks 
were initially propagated by infection of near-confluent HEp-2 cell monolayers with 0.1 
to 0.2 MOI virus. Supernatants and cells were collected and subjected to one freeze-
thaw cycle and then semi-clarified by centrifugation for 20 min at 1000 x g prior to snap 
freezing and storage at -80ºC. These stocks were then used to produce purified virus by 
infection of near-confluent HEp-2 cells with 0.1 to 0.2 MOI virus. After significant 
cytopathic effects were observed (5 to 6 days post-infection) the supernatants were 
collected and cells were scraped and briefly vortexed to release virions. Pelleted cells 
and debris were discarded in bleach while semi-clarified supernatant was treated with 
1M MgSO4 and transferred to an ultracentrifuge tube. A glycerol solution containing 
30% glycerol in 0.1M MgSO4 and 50mM HEPES buffer was carefully added to the 
bottom of the tube. Each tube was then spun in a Beckman ultracentrifuge at 11,600 
RPM for 3 hours at 4ºC. Afterwards the supernatant was carefully removed and each 
pellet was gently washed with 5ml OptiMEM to remove excess glycerol. Pelleted virus 
was resuspended in virus buffer containing 0.1M MgSO4, 150mM NaCl, and 50mM 
HEPES. Small aliquots were frozen and stored at -80ºC. Plaque forming unit assays 
were performed in HEp-2 cells to determine the number of infective virions per ml. Virus 
buffer alone was similarly frozen in small aliquots to be used as mock infection media. 
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Ultraviolet (UV) inactivation of virus was performed using a UV Stratalinker 1800 
(Stratagene, La Jolla, CA) by exposing virus resuspended in media to two rounds of 1 
joule UV irradiation.
2.2 Virus quantification
Viral titers from cell culture and homogenized tissues were determined using a 
plaque forming unit assay. Samples were centrifuged at 4°C for 10 min at 300 x g and 
serially diluted with serum-free media for infection in HEp-2 cells plated in 24-well cell 
culture plates and grown to 80% confluence. After an hour of infection at 37°C with 
frequent rocking the infection media was replaced with DMEM containing 0.8% 
methylcellulose, 5% FBS, L-glutamine, 100 units/ml penicillin, and 100 μg/ml 
streptomycin. After five days of growth the overlay was removed and plaques were fixed 
with 80% methanol overnight at 4°C. Fixative was removed and plaques were blocked 
with 5% non-fat milk in phosphate-buffered saline (PBS) at room-temperature for 30 
minutes. Plaques were labeled with a primary monoclonal antibody solution containing 
1:2000 dilution of mouse anti-RSV F (AbD Serotec, MCA490) for 2 hours at room 
temperature. Samples were washed three times for 5 min each and a solution of 
horseradish peroxidase (HRP)-conjugated anti-mouse secondary antibody diluted to 
1:2000 was added to plaques for an hour. Plaques were visualized using the 4CN 
substrate (Kirkegaard and Perry Laboratories) and counted manually and multiplied by 
the dilution factor to calculate the total number of plaque-forming units per mL of 
supernatant.
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2.3 Ribonucleic acid analysis
RNA was isolated from cell culture or mouse lung tissue using the TRIzol 
Reagent (Invitrogen) and chloroform/isopropanol precipitation method. After 
resuspension of precipitated RNA pellets with DEPC-treated water (Invitrogen) RNA 
was treated with DNase I (Roche, Germany) for 20 min. DNase enzyme was either 
deactivated heating with EDTA or removed by the RNeasy Mini Kit Clean Up (Qiagen) 
columns. RNA was converted into cDNA using reverse transcriptase enzyme (Maxima 
First Strand cDNA synthesis for qRT-PCR, Thermo Fisher Scientific) and cDNA 
template was diluted 1:5 with DEPC-treated water, then further diluted with 4X Yellow 
Sample Buffer for use with DyNAmo Flash SYBR Green qPCR reagent (Thermo 
Fisher). A PCR master mix was prepared by combining 2X Master mix, the appropriate 
forward or reverse primers (stock concentration 10 μM or 10X), and DEPC-treated 
water. 1 μL of diluted cDNA template was added to 4 μL of PCR master mix in individual 
wells of a 384-well clear PCR reaction plate (Thermo Fisher). Samples were run in 
triplicate and included no reverse transcriptase (NRT) and no template controls (NTC). 
The intercalated SYBR Green was measured with a BioRad CFX284TM Real-time PCR 
detection system. Data was analyzed using delta cycle threshold (∆Ct) and delta-delta 
Ct (∆∆Ct) derivations by comparing target gene expression to relative expression of the 
endogenous housekeeping genes GAPDH or HPRT. Melt curve analysis was used to 
evaluate gene specific amplification versus primer dimerization or nonspecific 
amplification. A list of the primers and their sequences is found in Table 1.
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2.4 Protein analysis
Cellular protein was isolated by freeze thaw method: cells were washed once 
with cold PBS, detached by scraping, and pelleted by centrifugation before adding 
freeze-thaw lysis buffer containing 600 mM KCl, 20 mM Tris-Cl (pH 7.8), 20% glycerol, 
and 1x each of protease and phosphatase inhibitor (EMD Chemicals Inc., San Diego, 
CA). Samples were submerged in liquid nitrogen for 5 minutes and thawed on ice for 5 
minutes three times. Cellular debris was removed by centrifuging at 13,200 x g for 5 
minutes. BCA protein analysis (Pierce Biotechnology, Rockford, IL) was performed on 
the supernatant to measure the protein concentration.
2.5 Western blot analysis
Cell lysates collected by freeze-thaw were separated based on size using SDS-
polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. 
Membranes were blocked in Tris-buffered saline (TBS; 0.05 M Tris-HCl and 0.2 M NaCl, 
pH 7.4) containing 0.1% (v/v) Tween-20 (TBST) and 5% non-fat milk (w/v) for 1 hour at 
room temperature then probed with the appropriate primary antibody. Primary 
antibodies used included mouse anti-human IDO (RayBiotech, Norcross, GA, USA) and 
mouse anti-human beta-actin (Sigma-Aldrich, St Louis, MO, USA). Each antibody was 
diluted in TBST containing 5% non-fat milk and used separately to avoid cross-reactivity 
or issues with their target protein sizes being similar. Probing was performed overnight 
at 4ºC. After rinsing the membranes were incubated with HRP-conjugated anti-mouse 
IgG for 1 hour at room temperature, and then rinsed again. Bands were visualized using 
the West Pico and West Femto (Pierce Biotechnology) and the ChemiDoc XRS+ 
Imaging System (Bio-Rad Laboratories, Hercules, CA, USA). Protein size was 
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determined by comparison with a biotinylated protein ladder (Cell Signaling Technology 
Inc., Danvers, MA) and the density of each band was quantified with ImageJ image 
analysis software [93] following a method detailed by Miller [94]. Results are reported as 
the relative abundance: a ratio of the density of the IDO band to the beta-actin band.
2.6 Enzyme-linked immunosorbant assay (ELISA) analysis
Conditioned media from MSCs infected with 1 MOI of RSV as previously 
described was clarified by centrifugation and the concentration of the immune regulator 
prostaglandin E2 (PGE2) was measured by ELISA (R&D Systems, Minneapolis, MN, 
USA). For IDO: Cell lysates were obtained by freeze-thaw as described previously and 
diluted for use in the ELISA kit for IDO (Cloud-Clone Corp., Houston, TX, USA). Each 
procedure was done in replicate and results shown were representative of repeated 
experiments.
2.7 Tryptophan catabolism assay
To assess the activity of IDO we performed a tryptophan catabolism assay. 
Protein from freeze-thaw lysates from MSCs were collected as described above and 
treated with buffer containing 100mM PBS, 40mM ascorbate, 20uM methylene blue, 
200ug/ml catalase, and 800uM L-tryptophan (pH 6.5). After a 30-minute incubation at 
37ºC the chemical reaction was stopped with 30% trichloroacetic acid and heating to 
52C for 30 minutes. Precipitate was removed and kynurenine in the supernatant was 
detected with Ehrlich’s reagent (0.8% p-dimethylaminobenzaldehyde in acetic acid) by 
reading absorbance at 490nm. Results are expressed as units per μg lysate where 1 
unit of IDO activity is defined as the amount of enzyme producing 1nmol per hour of 
kynurenine.
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2.8 Mitogen stimulation assay
To examine the effect of RSV infection on MSC regulation of lymphocyte 
responses peripheral blood mononuclear cells (PBMCs) were isolated from fresh buffy 
coats (Florida Blood Services, St. Petersburg, FL, USA) by centrifugation in Ficoll-
Paque PLUS (Amersham Pharmacia Biosciences, Uppsala, Sweden), counted, and 
labeled with carboxyfluorescein succinimidyl ester (CellTrace CFSE, Life Technologies). 
Stained cells were cultured in RPMI containing 10% FBS and 1% antibiotic and 
stimulated with the plant-derived T cell mitogen phytohemagglutinin (PHA) in the 
presence of MSCs or conditioned media from MSCs infected 48hrs prior. Proliferation of 
lymphocytes was assessed by flow cytometry 5 days later using an LSRII flow 
cytometer (BD Biosciences, San Jose, CA, USA). Results were analyzed using FlowJo 
software (Treestar, Ashland, OR, USA).
2.9 IDO activity, IFN-β signaling, RIG-I and endosomal TLR-pathway inhibitors
In order to investigate the contribution of IDO to the inhibition of PBMC 
proliferation human MSCs were infected with RSV as previously described. After 
removing infection media MSCs were incubated in complete MSC media containing the 
IDO-inhibitor 1-methyltryptophan (1-MT, Santa Cruz Biotechnology) at 1mM. After 48 
hours supernatants clarified by centrifugation were used in the PBMC proliferation 
assay as previously described. An alternative IDO inhibitor, vitamin K3 (menadione, 
Sigma-Aldrich, St Louis, MO, USA) [95] was used at 10μM to confirm the 1-MT results.
Additionally, to interrogate the pathways leading to IDO expression we treated 
RSV infected MSCs with either the endosomal TLR inhibitor chloroquine (10μg per mL, 
Sigma-Aldrich), the RIG-I pathway inhibitor BX795 (1μM, Invivogen, San Diego, CA, 
18
USA) or a neutralizing antibody to IFN-β (IFNb/A1, 10μg per mL, BioLegend, San 
Diego, CA, USA). Additionally the TLR3-specific inhibitor, TLR3-dsRNA Complex 
inhibitor (Calbiochem, San Diego, CA, USA) was used to interrogate that signaling 
pathway [96] at a 50 μM final concentration. The inhibitory oligonucleotide (iODN) ODN 
2088 (Innaxon, Tewkesbury, UK) was also used as a specific inhibitor to the TLR7, 8, 
and 9 pathways at a concentration of 50 μg per mL [97]. 
2.10 Mouse strains and methods
Wild type Balb/c and C57Bl/6 mice (WT) as well as B6.129-Ido1tm1Alm/J mice 
deficient in IDO (IDO-KO) were purchased from Jackson Laboratories. Mice were 
infected with RSV when they were 6-8 weeks old by intranasal administration under 
light anesthesia via inhaled isoflurane. Five days post infection the mice were 
euthanized and lungs were collected for histology, RNA, and PFU quantification as 
follows: The right bronchus was clamped shut while the left lung was perfused with 4% 
paraformaldehyde (PFA) in PBS via the trachea, then removed to a vial containing 4% 
PFA for histology. The right lobes were removed, minced, portioned into two 1.5 mL 
tubes, and snap-frozen on dry ice for RNA and plaque forming unit assays.
All animal procedures were reviewed and approved by the University of South 
Florida’s Institutional Animal Care and Use Committee and the VA Subcommittee on 
Research Safety, Animal Component of Research Protocol.
2.11 Mouse lung histology
After fixing overnight the lungs for histology were cryopreserved in 15% and then 
30% sucrose before embedding in Tissue-Tek OCT medium (VWR, Radnor, PA, USA) 
and freezing on dry ice. Five-micron sections were mounted on slides using a 
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cryomicrotome, dried in a humidified chamber and washed with PBS to remove 
embedding media. Then the sections were either directly stained with hemaxotoxylin-
eosin (HE) staining or steamed at 95ºC in unmasking solution (Vector Laboratories) for 
immunohistology. Sections were permeabilized with methanol and blocked for 30 
minutes with 5% bovine serum albumin (BSA) diluted in Tris-buffered saline containing 
0.1% Tween-20 (TBST). The primary goat anti-RSV (Millipore, Ab1128) was diluted in 
2.5% BSA in TBST and added to sections for overnight incubation at 4°C. Sections 
were washed and the secondary donkey anti-goat conjugated to Alexa Fluor 555 was 
similarly diluted and added to the tissue overnight, followed by washing and 
counterstaining with DAPI-containing anti-fade media (Vector Laboratories) and 
mounted with a coverslip for imaging. Fluorescent images were captured using an 
Olympus BX51 microscope with DP72 digital camera.
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Table 1. Real-time RT-PCR primers for human and RSV genes
Gene Ref Seq Primer Sequence (5'-3') Amplicon Exon Location
GAPDH NM 002046.3 IDT 103685527 CCACATCGCTCAGACACCAT 87 2 to 3
  IDT 103685147 AAAAGCAGCCCTGGTGACC   
RSVN M74568.1 IDT 103685155 CATCTAGCAAATACACCATCCA 70 N/A
  IDT 103686014 TTCTGCACATCATAATTAGGAGTATCAA   
IL1B NM 000576 IDT Hs.PT.51.20299051 AGGAGCACTTCATCTGTTTAGG 140 1 to 4
   GCCAATCTTCATTGCTCAAGTG   
IL-6 NM 000600.3 IDT 103685150 GATGGCTGAAAAAGATGGATGC 184 3 to 4
  IDT 103705045 CTGCAGGAACTGGATCAGGACT   
IL8 NM 000584 IDT Hs.PT.51.755000.g ACACAGAGCTGCAGAAATCAG 144 1 to 1
   TTTCAGAGACAGCAGAGCAC   
CXCL12 NM 000609 IDT Hs.PT.51.2268843 CATCTGTAGCTCAGGCTGAC 89 1 to 2
   ATGAACGCCAAGGTCGTG   
IFNA2 NM 000605 IDT Hs.PT.53a.24294810.g TTGACTTGCAGCTGAGCA 94 1 to 1
   CCCATTTCAACCAGTCTAGCA   
IFNB NM 002176 IDT Hs.PT.53a.28162302.g GTCAAAGTTCATCCTGTCCTTG 136 1 to 1
 CTCCACTACAGCTCTTTCCAT
IFNG NM 000619 IDT Hs.PT.53a.2672945 CGACAGTTCAGCCATCACTT 113 3 to 4
   GCAACAAAAAGAAACGAGATGAC   
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Table 1. (Continued)
Gene Ref Seq Primer Sequence (5'-3') Amplicon Exon Location
IL1RN NM 000577 IDT.Hs.PT.51.4381999 TTGTCCTGCTTTCTGTTCTCG 89 7 to 8
   CTGTCCTGTGTCAAGTCTGG   
IDO1 NM 002164 IDT Hs.PT.51.3356559 ACGTCCATGTTCTCATAAGTCAG 125 4 to 6
 GTTCCTTACTGCCAACTCTCC
NOS2 NM 000625 IDT Hs.PT.51.22593297 GAGCTCAGATGTTCTTCACTGT 99 1 to 2
   AAGTTCTCAAGGCACAGGTC   
CX3CR1 NM 001171174 IDT Hs.PT.53a.27377849.g CAGGTTCAGGAGGTAAATGTCG 109 5 to 5
CTACTCCGTCATCTTTGCCAT
CXCR4 NM 003467 IDT Hs.PT.51.22298491 CCTCGGTGTAGTTATCTGAAGTG 115 1 to 2
AGCAGGTAGCAAGTGACG
CXCR2 NM 001168298 IDT Hs.PT.51.309915 CTGTGACCTGCTGTTATTGGA 93 1 to 4
GTACAGTGCTATTCTGCCTAGA
TLR3 NM 003265.2 IDT 143665195 TTGCTCATTCTCCCTTACAC 256 3 to 3
IDT 143665196 CTTCGGAGCATCAGTCGT
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Table 2. Real-time RT-PCR primers for mouse genes
Gene Ref Seq Primer Sequence (5'-3') Amplicon Exon Location
mGAPDH NM 008084 IDT Mm.PT.39a.1 GTGGAGTCATACTGGAACATGTAG 150 2 to 3
 AATGGTGAAGGTCGGTGTG
mIFNB1 NM 010510.1 IDT Mm.PT.56a.30132453.g GGCATCAACTGACAGGTCTT 119 1 to 1
 ACTCATGAAGTACAACAGCTACG
mIDO1 NM 008324 IDT Mm.PT.58.42364388 AAGCTGCCCGTTCTCAATC 127 1 to 2
 AGACCACCACATAGATGAAGATG   
mNOS2 NM 001313922 IDT 134627193 CCAAGCCCTCACCTACTTCC 127 15 to 16
 IDT 134627194 CTCTGAGGGCTGACACAAGG
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Chapter 3: Respiratory Syncytial Virus Infection of Human 
Mesenchymal Stem Cells
3.1 Introduction
The finding that MSCs could also be target for RSV infection [76] suggested two 
important possibilities: that perhaps a stromal cell type in the lung or nasal mucosa 
could be an extra-epithelial target and reservoir for the virus and that the infection of 
these potent immune regulatory cells could contribute to RSV-mediated regulation of 
the immune system. Building on the work of Rezaee et al. (2011) [76] we first sought to 
characterize the infection of human mesenchymal stem cells (MSCs). We did this by 
infecting several different lines of both umbilical cord blood-derived and bone marrow-
derived MSCs. Multiple lines of these cells were purchased either from Vitrobiopharma 
(umbilical cord blood-derived MSCs) or Texas A&M (bone marrow-derived MSCs). 
Infection was confirmed by fluorescent microscopy and measuring viral RNA products 
by reverse transcriptase real-time PCR. RSV plaque forming units were quantified from 
cell culture supernatant to measure the productivity of the infection.
The results of this work confirmed that RSV productively infects human MSCs 
and that the infection can extend over 10 days, producing RSV transcripts detected by 
RTqPCR, protein products detected by antibody staining, as well as infective virions 
quantified by PFU assay.
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3.2 RSV infects human MSCs
Human MSCs were infected with rA2-KL19F at 1 MOI and fixed with 4% PFA at 
24, 48, and 72 hours post-infection. Fluorescent micrographs were captured to visualize 
RSV infected cells based on their mKate2 expression (red fluorescence) as well as all 
cells by nuclear staining with DAPI (blue) (Figure 1a). ImageJ analysis was performed 
using the cell counter plug-in to quantify the cells as well as the cells positive for RSV 
infection in each field (10 per well, 3 wells per time point, 4 human MSC lines) (Figure 
1b). Results showed that RSV infected 19% ± 4% cells were infected at 24 hours post 
infection, 72% ± 7% at 48 hours, and 81% ± 10% of MSCs were infected at 72 hours 
post infection (mean ± SD). 
As an alternative approach to confirm infection in MSCs cells were plated at 3 x 
105 cells per well in a 6 well plate with a sterilized collagen-coated 25mm round 
coverslip in the well. After 24 hours the MSCs were infected with RSV at 1 MOI in Opti-
MEM with 2% FBS or mock infection media for 90 minutes at 37C. The infection media 
was then aspirated and the wells were incubated with complete MSC media for 48 or 72 
hours. Media was aspirated and the cells were washed with PBS. Then the coverslip 
was removed and fixed in cold acetone before staining for RSV with an anti-RSV 
antibody conjugated to the fluorescent molecule FITC and containing the cytoplasmic 
stain Evan’s Blue which fluoresces red (#5022 Mouse anti-RSV+FITC monoclonal kit; 
Millipore, Billerica, MA, USA). The stained coverslip was washed with PBS and 
mounted on a slide upside down with mounting media containing 4,6-diamidino-2-
phenylindole (DAPI; Vector Laboratories, Burlingame, CA, USA). The results showed 
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specific staining of MSCs only on the RSV infected coverslips, confirming the result 
found using the red fluorescence-expressing virus (Figure 3).
3.3 Duration of RSV infection in human MSCs
To evaluate the duration of infection an experiment was designed utilizing the 
fluorescence of virally infected cells and a plate reader. Human MSCs were grown in a 
96-well plate and infected with 0.01, 0.1, or 1.0 MOI rA2-KL19F, UV-inactivated RSV, or 
mock infection media with 8 replicates of each treatment group. Cells were grown for 12 
days with media being refreshed every 3 days. Mean fluorescence intensity at excitation 
588 nm and emission 633 nm was assayed using the Synergy H4 Hybrid Multi-Mode 
Microplate Reader (BioTek Instruments, Inc., Winooski, VT, USA) (Figure 2). Results 
showed an extended infection in MSCs even at 1 infective unit per cell, peaking from 2 
to 4 days before fluorescence diminished. Cells infected with 0.01 MOI or 1 infective 
unit per 100 cells had a slower and longer infection, peaking at 6 day to 9 days. 
Interestingly, in the RSV-infected groups some human MSCs remained even after red 
fluorescence intensity returned to mock and UV-inactivated levels, indicating that 
perhaps some resistant cells grew out or the virus infection was self-limiting, or perhaps 
became abortive or latent at some point in time. As a note: the UV-inactivated virus was 
used at all the same MOIs as the active virus, however the results for each MOI of 
inactivated virus were similar and for simplicity and readability of the figure only the 
highest MOI was shown. This result is consistent with some other long-term RSV 
infection studies in other cells types such as dendritic cells, macrophages or HEP-2 
cells which have been reported to support prolonged persistent infections [70, 98-101].
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3.4 Plaque forming unit and viral transcript quantification
To evaluate whether the productivity of RSV infection in human MSCs the culture 
supernatants from infected cells or mock-infected cells were collected and plaque 
forming unit assay was performed as described previously. Briefly, HEP-2 cells were 
infected with varying dilutions of supernatant for 90 minutes rocking at regular intervals. 
Infection media was removed and warmed growth media containing 5% methylcellulose 
was added. The principle of the assay is to limit the viral spread to just the neighboring 
cells allowing the detection of individual infective units. Results from this assay show 
that RSV replicates in human MSCs and produces infective virions that are released 
from the cells into the culture supernatant (Figure 4a).
Additionally, expression of the RSV specific transcript for the RSVN gene was 
measured in human MSCs. Briefly, MSCs were infected as previously described for 6, 
12, 24, or 72 hours prior to collection of total RNA using the TRIzol method. RNA was 
purified and cleaned using a DNase I treatment (Roche) as well as an RNA cleanup 
step (RNeasy Mini Kit, Qiagen). After reverse transcription of the mRNA to cDNA the 
expression of RSVN was measured using predesigned primers (Integrated DNA 
Technologies). Gene expression was normalized to the cellular housekeeping gene 
GAPDH and results were reported as expression relative to uninfected cells (Figure 4b). 
Statistical analysis confirmed that RSVN was detectable in the infected MSCs at all time 
points, increasing from 6 to 72 hours post infection. These results, in concert with those 
reported above, confirm the viral infectivity and productivity of MSCs with respect to 
RSV and reveal the potential for in vivo infection of this important regulatory cell type in 
natural infection.
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A.
Figure 1. RSV infection of human MSCs (Continued on next page)
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B.
Figure 1. RSV infection of human MSCs (Continued)
Four lines of human MSCs infected for 24, 48, or 72 hours with 1 MOI of 
virus were captured with a fluorescent microscope for mKate2 (red) expressing cells as 
well as DAPI (blue) stained cells (A). Percentage of cells infected reported as red cells 
divided by total nuclei, quantified by ImageJ analysis (B). The mean percent infected is 
shown with the error bars representing the standard deviation, n = 4.
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Figure 2. Duration of RSV infection in human MSCs
The mean fluorescent intensity of infected MSCs at excitation/emission of 
588/633 nm was assessed over 12 days. Results reported as MFI normalized to the 
fluorescent intensity detected in the mock-infected group. Each group had an n = 8 and 
error bars represent the standard deviation.
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Figure 3. Staining of infected MSCs with a RSV-specific antibody
Human MSCs grown on coverslips, infected with 1 MOI of RSV, and 
immunostained at 48 or 72 hours post-infection with a monoclonal antibody to RSV 
tagged with FITC (green), Evan’s blue dye (red) and DAPI (blue). Total magnification of 
images is 200X (inset 1000X) and scale bar is 50μm. Results characteristic of multiple 
experiments and fields of view.
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Figure 4. Plaque forming unit assay and quantification of RSVN transcript in 
infected MSCs
Infective virions collected from cell culture supernatants were detected and 
quantified by PFU assay in HEP-2 cells by serial dilution and indicated that RSV 
infected MSCs are capable of producing infective viral progeny (A). RSVN transcripts 
detected in MSCs at 6, 12, 24 and 72 hours post infection normalized to mock  (B). 
Results representative of multiple experiments, each done with 3 replicates per group, 
error bars represent SD. * p < 0.05, ** p < 0.01, *** p < 0.001
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Chapter 4: Cytokine and chemokine response of RSV-infected MSCs
4.1 Introduction
The immune system coordinates a response to RSV infections via the production 
and secretion of a number of bioactive signaling molecules called cytokines and 
chemokines. Proinflammatory cytokine activity can leads to increased blood circulation 
and immune cell infiltration. This immune cell signaling manifests as the symptoms 
experienced by infected patients; fever, inflammation, mucus hyper-secretion, and 
obstruction of the airways. Many proinflammatory cytokines have been shown to 
increase in the airway during RSV infection, including interleukin (IL)-6, IL-1β, IL-8 (or 
CXCL8), tumor necrosis factor (TNF) α, RANTES (regulated on activation normal T cell 
expressed and secreted, or CCL5), macrophage inflammatory protein (MIP)-1α, MIP-1β 
(or CCL4), eotaxin, and a host of others [102-106]. These cytokines, and others such as 
like IL-1α and IL-33, are secreted upon stimulation of pathogen recognition receptors 
(PRRs) by viral factors [107] and result in infiltration, inflamation, and mucus hyper-
secretion as well as tissue remodeling in the airway.
Interestingly, mouse models have shown that the cytokine profile may depend on 
the viral strain or even a single protein. For example, reports indicate that murine 
lymphocytes treated with the RSV envelope G protein of RSV were stimulated in vitro 
and released Th2-like cytokines [108] while the envelope F protein stimulated Th1-
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promoting cytokines [109, 110]. Even different strains of the virus, such as the lab strain 
A2 and clinical isolates have been found to have varying cytokine responses [21, 111-
115] and changing a single protein can have dramatic effects on the manifestation of 
RSV induced disease [116]. Additionally, age of infection has also been found to 
influence cytokine profile and infection duration [21, 106]. It is possible that different 
individual outcomes to RSV infections, such as more severe disease or recurrent 
wheeze later in life, could be due to this diverse response to viral components.
The aim of the following experiments was to evaluate the cytokine response of 
human MSCs after RSV infection. A panel of important inflammatory, viral response, 
and immune regulatory factors were assayed for expression by reverse transcription 
qPCR . This response was compared with that seen in the traditional target cell type for 
RSV, normal human bronchial epithelial (NHBE) cells.
4.2 RSV induction of inflammatory cytokine and chemokine expression 
To investigate the cytokine responses to RSV infection in human MSCs total 
RNA was isolated after 72 hours of infection, reverse transcribed to cDNA, and used in 
a qPCR reaction as previously described. Results indicated that unlike NHBE cells, 
which expressed increased the proinflammatory cytokines IL-6 (4.6-fold, p = 0.0220) 
and stromal cell-derived factor (SDF)-1 (or CXCL12, 2-fold, p = 0.0457), RSV-infected 
MSCs expressed more IL-8 (or CXCL8, 2.85-fold, p = 0.0291) than mock-infected cells 
(Figure 5). Additionally, the antiviral response factors IFN-α, IFN-β, and IFN-γ were 
examined after RSV infection. An increase in IFN-β transcripts was observed for both 
RSV infected NHBE cells (2.41-fold, p = 0.0334) and MSCs (106.9-fold, p = 0.0036) 
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compared to mock but no change in either IFN-α or IFN-γ were found in either cell type 
(Figure 6).
Also, receptors for selected chemokines were also assayed for expression after 
infection with RSV by RTqPCR; CX3CR1 (fractalkine receptor), CXCR2 (IL-8 receptor, 
beta), and CXCR4 (or fusin, the receptor for SDF-1). Interestingly, while infected NHBE 
cells did not show any increase in transcripts for the receptors measured RSV-infected 
MSCs showed a 5.2-fold increase in CXCR4 expression compared with mock (p = 
0.0085) (Figure 7).
4.3 Immune regulatory factor expression during RSV infection
RSV-infected NHBE cells and MSCs were tested for expression of the immune 
regulatory factors IL-1 receptor antagonist (IL-1ra), inducible nitric oxide synthase 
(iNOS) and IDO (Figure 8a). RSV infection increased IDO transcripts 68.9-fold 
compared to mock infected (p=0.0023) in MSCs. A significant but less dramatic 5.9-fold 
increase was also observed for in RSV infected NHBE cells (p=0.0120). No changes in 
IL-1ra or iNOS were seen at 72 hours post infection. As another potential immune 
regulatory pathway, prostaglandin E2 (PGE2) level was measured by ELISA (Figure 8b). 
RSV-infection was not associated with any change in PGE2 levels in MSC culture 
supernatant.
4.4 Dynamics of cytokine and immune regulatory factor expression throughout 
the infection
While the previous results provided a list of important cytokines, receptors, and 
immune regulators during RSV infection of MSCs the next step was to investigate the 
expression of these genes over the course of the infection. Human MSCs were infected 
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with RSV and RNA was collected from these cells as previously described at 5 times 
points; 6, 12, 24, 48, and 72 hours post infection. Results showed a steady increase of 
IFN-β expression from 6 to 72 hours during RSV infection, with the increase achieving 
significance at 12, 24, 48, and 72 hours versus mock (Figure 9a); 7.9-fold at 12 hours (p 
= 0.009), 65.7-fold at 24 hours (p = 0.004), 78.5-fold at 48 hours (p = 0.045), and 110.9-
fold at 72 hours post infection (p < 0.001). Conversely, IFN-γ did not show any 
significant change in expression compared with mock-infected MSCs at any of the time 
points tested (Figure 9b). The expression of IDO transcripts were slightly delayed 
compared with IFN-β, only reaching significance at 24, 48, and 72 hours post infection 
(Figure 9c); 15.9-fold at 24 (p = 0.03), 108.3-fold at 48 (p < 0.001), and 70.2-fold at 72 
hours post infection (p < 0.001). In contrast to IFN-β and IDO expression the levels of 
CXCR4 transcripts followed a cyclical pattern, elevated compared to mock at 6 (3.4-fold, 
p = 0.06), 24 (4.5-fold, p = 0.047), and 72 hours post infection (5.2-fold, p = 0.0029) 
while dropping back to quantities similar to mock-infection when measured at 12 and 48 
hours post infection (Figure 9d).
4.5 Indoleamine-2,3-dioxygenase activity in RSV infected MSCs
As a potent immune regulator IDO expression in RSV-infected MSCs was of particular 
interest. Therefore, Western blot analysis was performed on protein collected by freeze-
thaw from infected or mock-infected MSCs at 24 and 48 hours post infection, as 
previously described. The results confirmed the presence of IDO protein in MSCs at 
both time points (Figure 10a). At 24 and 48 hours RSV-infected MSCs showed a 0.54 
and 0.12 relative abundance to beta actin respectively while mock-infected MSC lysates 
showed 0.08 and 0.06 relative protein abundance at the same time points; a 6- and 2-
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fold increase at 24 and 48 hours due to RSV infection. The gold standard in assaying 
enzymes is to measure their activity, therefore a tryptophan catabolism assay was 
performed using the lysates from infected and mock MSCs at 24 and 48 hours post 
infection (Figure 10b). Briefly, freeze-thaw lysates from RSV-infected MSCs were 
treated with tryptophan catabolism buffer for 30 minutes at 37ºC before stopping the 
reaction and measuring kynurenine in the supernatant with Ehrlich’s reagent. The 
results are expressed as IDO units per μg lysate where 1 unit of IDO activity is defined 
as the amount of enzyme producing 1 nanomole of kynurenine per hour. IDO activity 
was detected in RSV-infected MSCs at 24 and 48 hours while no activity was detected 
in mock-infected MSCs.
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Figure 5. Cytokine expression in MSCs following RSV infection differs from NHBE 
cells
Cytokine transcription in RSV-infected NHBE cells and MSCs after 72 hours post 
infection by RTqPCR reported as fold expression compared to mock-infected NHBE 
and MSCs. Infected NHBE had higher IL-6 and SDF-1 transcripts while infected MSCs 
had increased IL-8 expression. The dashed line shows expression in mock treated cells 
and error bars represent the standard error of the mean (SEM); Statistical analysis by 2-
way ANOVA, n = 6 for both cell types and treatments. * p < 0.05 vs. mock
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Figure 6. RSV infection increases IFN-β transcription in human MSCs and NHBE 
cells
Interferon transcript expression in RSV-infected NHBE and MSCs compared to 
mock-infected cells. IFN-β expression was increased in both NHBE (2.409-fold, p = 
0.0334) and MSCs (106.9-fold, p = 0.0036) compared with mock-infection. The dashed 
line shows expression in mock treated cells and error bars represent the standard error 
of the mean (SEM); Statistical analysis by 2-way ANOVA, n = 6 for both cell types and 
treatments. * p < 0.05, ** p < 0.01 vs. mock
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Figure 7. Chemokine receptor CXCR4 expression increased in MSCs after RSV 
infection
Selected chemokine receptor transcription in RSV-infected NHBE cells and 
MSCs after 72 hours post infection by RTqPCR reported as fold expression compared 
to mock-infected NHBE and MSCs. RSV-infected MSCs showed a 5.2-fold increase in 
CXCR4 expression compared with mock (p = 0.0085). NHBE cells did not show any 
increase in transcripts for the receptors measured. The dashed line shows expression in 
mock treated cells and error bars represent the standard error of the mean (SEM); 
Statistical analysis by 2-way ANOVA, n = 6 for both cell types and treatments. ** p < 
0.01 vs. mock
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Figure 8. Immune regulatory factor expression during RSV infection
The expression of IL-1Ra, IDO and iNOS were examined in RSV- or mock-
infected NHBE cells and MSCs after 72 hours post infection by RTqPCR, reported as 
fold expression compared to mock. The expression of IDO in both NHBE cells and 
MSCs was increased after infection with RSV while transcripts of IL-1 receptor 
antagonist and iNOS were not different from mock (A). PGE2 expression was assessed 
by ELISA and showed no change in RSV- versus mock-infected MSCs (B). * p < 0.05, 
** p < 0.01
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Figure 9. Temporal dynamics of RSV-induced transcripts in human MSCs 
(Continued on next page)
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Figure 9. Temporal dynamics of RSV-induced transcripts in human MSCs 
(Continued)
Human MSCs were infected with RSV and RNA was collected from these cells 
as previously described at 5 times points; 6, 12, 24, 48, and 72 hours post infection. 
Transcripts from RSV-infected human MSCs revealed a steady increase in IFN-β from 6 
to 72 hours post infection (A). IFN-γ expression was not significantly changed in RSV-
infected compared with mock-infected MSCs at any of the time points (B). The change 
in expression of IDO transcripts reached significance at 24, 48, and 72 hours post 
infection (C). The levels of CXCR4 transcripts followed a cyclical pattern, higher 
compared to mock at 6, 24, and 72 hours post infection and at mock-infection levels 12 
and 48 hours post infection (D). RSVN transcript was measured and showed a steady 
increase in viral transcripts consistent with a productive infection (E). Results shown are 
typical of replicated experiments. n = 3 for 6, 12, and 24 hours, n = 6 for 48 and 72 hour 
time points. * p < 0.05, ** p < 0.01, *** p < 0.001
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Figure 10. Western blot and enzymatic activity of IDO in infected MSCs
The presence of IDO protein in RSV-infected MSCs was confirmed by Western 
blot (A). Activity of the enzyme was measured using MSC lysates at 0, 24 and 48 hours 
after infection by tryptophan catabolism assay and indicated active IDO following RSV 
infection (B).
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Chapter 5: Role of Mesenchymal Stem Cells in Respiratory Syncytial 
Virus Immune Regulation by Indoleamine-2,3-dioxygenase
5.1 Introduction
Indoleanime-2,3-dioxygenase (IDO) was first described in 1963 [117, 118] as an 
alternative enzyme to typrtophan-2,3-dioxygenase (TDO) in the oxidative catabolism of 
tryptophan [119]. These enzymes catalyze the conversion of tryptophan to formyl-
kynurenine. TDO and IDO are members of a small family of heme-containing enzymes, 
and while TDO is found in both prokaryotes and eukaryotes IDO has only been 
identified in eukaryotes [120, 121]. There are two IDO genes in eukaryotes, IDO1 and 
IDO2. IDO2 appears to be the ancestral form, found in lower vertebrates, while IDO1 is 
hypothesized to have arisen by gene duplication during tetrapod evolution [122]. 
Mammalian expression of TDO is limited to the liver, however IDO mRNA can be found 
expressed in a diverse array of extra-hepatic cell types and tissues [123]. Interest in 
IDO as a regulator of immune responses arose when its role in preventing maternal 
rejection of the fetus was discovered [124]. 
Of the essential amino acids tryptophan is the most limited, and as a 
consequence protein synthesis and therefore cell activity, growth, and division are all 
dependent on the availability of tryptophan [125]. IDO activity has been shown to have 
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an anti-proliferative function on cells that can be reversed by exogenous tryptophan 
[126]. It has been estimated that 99% of tryptophan enters the IDO catabolism pathway 
[127]. The catabolic activity of IDO and its protein level expression are highly regulated, 
as activation of IDO can rapidly reduce tryptophan concentrations to nanomolar levels 
[127, 128].
This tryptophan depletion presents a potential antimicrobial and antiviral strategy, 
by imposing a condition of amino acid starvation on pathogens and limiting production 
of viral products [129, 130]. In parasitic infection by Toxoplasma [131, 132] and 
Trypanosoma cruzi [133] IDO expression has been found to be beneficial and limited 
the growth of the parasites while conversely in Leishmania infections IDO induction in 
infected dendritic cells is associated with immune escape by the parasite [134]. The 
pathogenesis of some bacterial infections have been linked to IDO, such as 
Mycobacterium leprae and tuberculosis (145) and streptococcal toxic shock-like 
syndrome (143). Activation of IDO has also been linked to viral infections including 
hepatitis C [135]. In studies of influenza IDO expression has been implicated in 
reduction of memory B cells following primary infection, decreasing the secondary 
immune response upon future infection [136-140].  Infections with human 
immunodeficiency virus (HIV) has been shown to induce IDO, associated with both 
reduced CD4+ T-cell activation and also the HIV-associated depression and weight loss 
potentially due to depletion of tryptophan, the precursor to the neurotransmitter 
serotonin [141]. Conversely, during herpes simplex viral infections IDO induction 
appears to be beneficial and has been found to reduce viral replication [142]. 
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IDO activity has a wide range of immune modulatory effects [143], including 
immunosuppression by limiting proliferation in CD4 and CD8 T cells as well as NK cells. 
Additionally, tryptophan depletion as well as tryptophan metabolites have been 
suggested to be involved in modulation of Th1 versus Th2 type responses [144, 145]. 
IDO activity induces apoptosis in proliferating T cells, preferentially in Th1 versus Th2 
cells [146], potentially shifting the balance between the two responses. Antigen 
presenting cells, such as macrophages, have been shown to have a specialized highly 
efficient tryptophan-transport system which allows them to resist the tryptophan 
starvation effects of IDO activity, while T cells have been shown to only use the 
conventional tryptophan transport mechanism [128]. Immune regulation by IDO has 
been considered one of several mechanisms for tumor immune escape, observed in a 
number of cancer malignancies including colorectal cancer and T cell leukemia [147, 
148].
In order to evaluate the effect of RSV infection on immune regulation by MSCs a 
mitogen-stimulation assay with PBMCs either cultured or treated with conditioned media 
from MSCs was used. Two IDO-specific inhibitors were utilized to investigate the role of 
IDO in this process. Results implicated IDO as one of the factors produced by cells 
following RSV infection that contributes to immune regulation by the virus.
5.2 Secreted factors from RSV-infected human MSCs regulate lymphocyte 
proliferation
A mitogen proliferation assay was employed to investigate the effect that MSC 
infection by RSV may have in immunity. Human PBMCs were isolated from fresh buffy 
coats as previously described and stained with CFSE at 2.5 μM and grown with or 
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without stimulation by PHA, a plant-derived mitogen. Several growth conditions were 
assayed in order to evaluate the immune regulatory effects of human MSCs after RSV 
infection: control cells not treated with MSCs or MSC conditioned media; PBMCs 
cultured directly with MSCs; and PBMCs treated with conditioned media from MSC 
cultures or fresh complete MSC media as a control (1:1 mix with RPMI-10). After 5 days 
at 37ºC the PBMCs were collected and CFSE fluorescence was analyzed by flow 
cytometry.
Results indicated that PBMCs treated with cell culture supernatant from infected 
MSC cultures had significantly reduced proliferation compared to PHA control (29.4% 
versus 76.9%, p < 0.0001) while those treated with media from uninfected MSCs were 
not significantly affected (75.5% versus 76.9%, p = 0.5633) (Figure 11b). The human 
PBMCs that were cultured directly with human MSCs showed no proliferation 
regardless of whether the MSCs were infected with RSV or not; RSV-infected MSCs: 
4.52% (p = 0.3885); mock-infected MSCs: 3.94% (p = 0.5633) (Figure 11c).
Next, to further analyze the effect of secreted factors from MSCs on human 
PBMC proliferation we tried varying amounts of CM from MSCs. Results showed a 
dose-dependent decrease in mitogen-stimulated proliferation of PBMCs treated with the 
CM from either RSV- or mock-infected MSCs (Figure 12). As found previously, the cells 
treated with CM from MSCs infected with RSV had significantly lower proliferation than 
those treated with mock at all concentrations tested. PBMCs cultured with 25% CM from 
RSV-MSCs showed 40% less proliferation than those cultured with CM from mock-
MSCs (46% vs. 86%, p = 0001). Similarly, PBMCs cultured with 50% or 75% CM 
showed a reduction in PHA-stimulated proliferation, 37% less (37% vs. 74%, p < 
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0.0001) and 15% less (18% vs. 33%, p = 0.0234), respectively. These results showed 
that RSV infection increased the regulatory effect of MSCs via factors in the CM.
These results indicated that there was some factor or factors secreted by 
infected MSCs that could down regulate the proliferation of PBMCs in response to a 
mitogen. Based on the previous results we hypothesized that an IDO metabolite 
kynurenine could be one of the factors involved. Based on the lowest p-value (i.e. 
largest statistical difference) seen between infected and mock CM during the 
concentration experiments we chose to perform the following experiments with 50% 
MSC CM treatment.
5.3 IDO metabolite kynurenine plays a role in MSC-mediated immune regulation
In order to test out hypothesis that increased IDO production by RSV-infected 
MSCs was responsible for modulating PBMC expansion we used the IDO activity 
inhibitor 1-MT. This molecule acts as a competitive inhibitor, binding to the same site on 
IDO as tryptophan. The human MSCs were infected as previously, however in the 
treatment group the infection media was replaced with MSC media containing 1-MT at a 
concentration of 1 mM. The rest of the experiment was performed as previously 
described with PBMCs being treated with MSC CM or MSC media as a control, diluted 
1:1 in RPMI-10.  PBMCs treated with CM from RSV-infected MSCs showed a significant 
reduction in mitogen-stimulated proliferation (38.77%) compared with mock (72.64%; P 
< 0.0001) (Figure 13a). Treatment of MSCs with 1-MT during the RSV infection restored 
the mitogen-stimulated proliferative capacity of PBMCs (66.27%; p < 0.0001 versus 
RSV-MSC CM; not significantly different from mock-infected MSCs, p = 0.17). Similar 
results were found when MSCs were treated with the alternative IDO activity inhibitor 
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vitamin K3 (71.40%; versus mock CM p = 0.7771, versus RSV-MSC CM p < 0.0001). To 
demonstrate that this reversal on immune regulation by infected MSCs was not due to 
inhibition of viral replication by these IDO inhibitors flow cytometry, RTqPCR, and 
plaque assay were performed (note: vitamin K3 caused auto-fluorescence in mock-
infected MSCs and was excluded from the FACS analysis). These showed that the 
inhibitors had no effect on RSV infection or productivity (Figure 13b and c). Kynurenine 
concentrations in the supernatants of MSC cultures were measured with Ehrlich’s 
reagent following the second half of the tryptophan catabolism assay described 
previously. Results showed that media from infected MSCs treated with the IDO 
inhibitors had a lower kynurenine concentration than untreated cells (Figure 13d).
Taken together, these results demonstrate the potential immune regulatory role 
of IDO production by MSCs in RSV infection, an effect that was reversed in the 
presence of either of the IDO inhibitors. To understand this result better the next step 
was to determine the mechanism behind the observed RSV-induction of IDO and 
subsequent inhibition of PBMC proliferative capacity.
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Figure 11. Conditioned media versus co-culture treatment of PBMCs with RSV-
infected human MSCs (Continued on next page)
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Figure 11. Conditioned media versus co-culture treatment of PBMCs with RSV-
infected human MSCs (Continued)
RSV or mock-infected human MSCs were used to treat PBMCs prior to mitogen 
stimulation with PHA and proliferation assay measured by CFSE fluorescence. Three 
replicates were performed for each treatment and histograms of representative FACS 
reports are shown for each group and the mean of each group inlayed on the graph. 
Control PBMCs were not treated with MSC cell culture supernatant and averaged 
76.9% dividing cells (A). PBMCs treated with cell culture supernatant from infected MSC 
cultures had significantly lower proliferation compared to PHA control (p < 0.0001) while 
those treated with media from uninfected MSCs were not significantly affected (p = 
0.5633); 29.4% and 75.5% dividing PBMCs respectively (B). PBMCs cultured directly 
with human MSCs infected or not infected with RSV showed no proliferation with 4.52% 
and 3.94% of cells dividing, not significantly different from PBMCs not receiving mitogen 
stimulation (p = 0.3885 and 0.5633) (C). A graph summarizing the data; bars show the 
mean and error bars represent the standard deviation (D). **** p < 0.0001 vs. PHA 
control, † no significant difference vs. unstimulated control
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Figure 12. Conditioned media from RSV-infected MSCs reduces PBMC 
proliferation in a dose-dependent manner
Freshly isolated PBMCs stained with CFSE, treated with either RSV or mock 
conditioned media, and grown in triplicates with (line) or without PHA (shaded) for 5 
days. CFSE fluorescence was measured by flow cytometry as an indication of 
proliferation; representative histograms from the 50% CM treated groups are shown (A). 
The proliferation of PBMCs treated with conditioned media from RSV-infected MSC was 
reduced in a dose-dependent manner (B).  Result of a representative experiment is 
shown. Groups compared by one-way ANOVA with Fisher’s LSD test, error bars 
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represent standard error of the mean (SEM), n = 3. * p < 0.05, *** p < 0.001, **** p < 
0.0001 vs. mock MSC CM treatment
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Figure 13. Indoleamine-2,3-dioxygenase inhibitors block infected MSC regulation 
of PBMCs
Freshly isolated PBMCs stained with CFSE, treated CM from MSCs, and 
cultured for 5 days with the mitogen PHA. Flow cytometry for CFSE fluorescence as a 
measurement of PBMC proliferation showed that 1-MT and vitamin K3 treatment during 
infection of MSCs returned PBMC proliferation to mock levels (A). This effect was not 
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due to a reduction in RSV infection shown by flow cytometry (B), PFU assay, and RSVN 
expression (C). The concentration of kynurenine in the supernatants of infected MSCs 
treated with the IDO inhibitors was lower than untreated cells (D). Significance between 
groups determined by one-way ANOVA with Fisher’s LSD test. Results representative 
of duplicate experiments, error bars represent SEM, n = 3. **** p < 0.0001
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Chapter 6: Mechanism of RSV-mediated Indoleanime-2,3-dioxygenase 
Induction in Mesenchymal Stem Cells
6.1 Introduction
Several pathways of IDO induction have been identified. IDO can be induced by 
addition of type I or type II interferons, microbial components such as LPS or dsRNA, 
prostaglandins, and soluble forms of the immune regulatory receptor cytotoxic T 
lymphocytes-associated antigen 4 (CTLA-4) [149, 150]. This distinguishes IDO from the 
other major tryptophan catabolism enzyme TDO, which does not appear to be inducible 
immunologically [128]. Negative regulation of IDO has been demonstrated in monocytes 
by IL-4 [151] and in fibroblast by TGF-β [152].
While the major pathway of IDO induction in MSCs appears to be through IFN-γ 
signaling there are many studies demonstrating IFN-γ-independent pathways; IL-18 and 
IL-12 [153], and IFN-β [154, 155]. Also, HIV has been found to induce IDO activity in an 
interferon-independent fashion [156]. A recently described IFN-γ-independent pathway 
resulting the production of IDO involves IFN-β [154, 155]. In contrast to IDO stimulated 
by IFN-γ, which functions as an immune regulator through its enzymatic catabolism of 
tryptophan, IFN-β-induced IDO has been shown to act as a signaling molecule, which 
when phosphorylated at its two immunoreceptor tyrosine-based inhibitory motifs 
57
(ITIMs), can lead to RelB/p52-mediated activation of the NF-κB pathway, and promote 
IFN-β and TGF-β expression [157].
The lack of IFN-γ expression in MSCs and NHBE cells during RSV infection 
coupled with the results presented previously of high IFN-β expression led to the 
investigation of this signaling pathway as a potential mechanism of IDO induction. 
Results from this study demonstrated the importance of IFN-β signalling in the induction 
of IDO during RSV infection. Additionally, we used various PRR pathway inhibitors to 
determine their roles in the expression of IFN-β in response to RSV, demonstrating a 
potential pathway from RSV recognition by MSCs to downstream immune regulation. 
6.2 IFN-β signaling drives IDO production in RSV-infected MSCs
Next the hypothesis that IFN-β signaling was driving the expression of IDO in 
MSCs infected by RSV was investigated. Using a neutralizing antibody we blocked IFN-
β signaling through its surface receptor. Briefly, 10 μg per ml of the anti-IFN-β antibody 
was added to the culture supernatant of MSCs infected with RSV immediately following 
infection. After 72 hours the supernatants were removed and RNA was collected by the 
TRIzol method, as previously described, to examine the effect of blocking IFN-β on IDO 
expression.
Blocking IFN-β signaling with a neutralizing antibody reduced IDO expression in 
RSV-infected MSCs compared with untreated cells (Figure 14a). Cell lysates from cells 
with showed significantly lower IDO protein, measured by ELISA, as well as IDO 
enzymatic activity, measured by tryptophan catabolism assay (Figure 14b and c). 
Untreated RSV-infected MSCs had a mean activity of 48.76 units of IDO per μg lysate 
compared to infected MSCs blocked with anti-IFN-β, which had a mean activity of 18.85 
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units per μg lysate. This reduction in RSV-induced IDO gene expression (9.6-fold in 
anti-IFN-β treated versus 24.9-fold in untreated cells) was not due to a reduction in IFN-
β transcript epression (Figure 14d). This established the involvement of the IFN-β 
signaling pathway in IDO-induction during RSV infection of MSCs. 
6.3 The role of the RIG-I and endosomal TLR pathways in IFN-β induction during 
RSV infection of MSCs
To examine the upstream PRR signaling leading to IFN-β expression and 
signaling during RSV infection, and subsequent IDO expression and activity, a series of 
inhibitors were used. In the first series of experiments a RIG-I pathway inhibitor BX795, 
which blocks phosphyrlation and thereby catalytic activity of TBK1/IKKε [158], was used 
as well as chloroquine, a broad inhibitor of endosomal pathways including endosomal 
TLR signaling [159, 160] through TLR3, 7, 8, and 9. As described previously, MSCs 
were infected with RSV and then cultured in the presence of either normal MSC growth 
media or growth media containing one of the inhibitors. After 72 hours the RNA, cell 
lysates, and supernatants were collected and used to measure IFN-β and IDO 
transcripts, IDO protein and activity, and PFU production by RSV.
Expression of IFN-β was significantly reduced in MSCs treated with chloroquine 
(121.7-fold versus 285.3 in untreated cells; p = 0.002), while the BX795 group did not 
show a statistical difference in IFN-β transcripts (201.6-fold; p = 0.135) (Figure 15a). 
IDO expression was only 3.7-fold for chloroquine treatment versus 31.2-fold for BX795 
treatment and 24.9-fold in untreated infected MSCs (Figure 15b). ELISA of cell lysates 
showed a significant drop in IDO protein concentration in chloroquine treatment (240.7 
pg per μg lysate) versus untreated cells (355.0 pg per μg lysate; p  = 0.0009) while 
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BX795 was not statistically different (395.3 pg per μg lysate) (Figure 15c). Activity of 
IDO, measured by tryptophan catabolism, was significantly reduced in chloroquine-
treated cells as well (22.95 units of IDO per μg lysate) compared with untreated cells 
(48.76 units of IDO per μg lysate; p = 0004) (Figure 15d). These changes in expression 
were not due to an effect of the inhibitors on RSV infectivity or replication, measured by 
PFU in the culture supernatant (Figure 15e).
Similar to the treatment with the anti-IFN-β antibody reported above treating the 
cells with chloroquine reduced IDO protein detected by ELISA as well as enzymatic 
activity in lysates from infected cells, while cells treated with the RIG-I pathway inhibitor 
BX795 were unaffected. These results indicate that endosomal TLR pathways may be 
responsible for recognizing and responding to RSV infection in MSCs, triggering IFN-β 
expression and downstream IDO expression and activity.
6.4 Blocking TLR7/8/9 and TLR3 signaling with specific inhibitors
To determine the endosomal pathway or pathways responsible for the IFN-β 
response to RSV in MSCs we used two specific inhibitors; ODN 2088, a short single-
stranded inhibitory oligodeoxynucleotide (ODN) that antagonizes CpG ODN-mediated 
activation of TLR9 as well as inhibiting TLR7 and TLR8 activity [161-163] and 
TLR3/dsRNA Complex Inhibitor, a direct competitive and high affinity inhibitor of dsRNA 
binding to TLR3 [96]. 
For ODN 2088, MSCs were infected with RSV and then grown in MSC growth 
media with the inhibitors or no inhibitor (vehicle for ODN 2088). After 72 hours of 
infection the RNA was collected and used to measure IFN-β, IDO, TLR3 and RSVN 
transcript production by RSV infected cells. Results showed that ODN 2088 treatment 
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did not change how MSCs responded to RSV infection in terms of their IFN-β 
expression (73.4-fold vehicle versus 66.9-fold ODN 2088, p = 0.182); IDO expression 
(63.3-fold versus 66.8-fold, p = 0.5143); or TLR3 expression (26.7-fold versus 27.2-fold, 
p = 0.72).
For the TLR3/dsRNA complex inhibitor, MSCs were infected as described 
previously and grown in the presence of TLR3-inhibitor or DMSO (vehicle control for the 
TLR3-inhibitor) for 24 and 48 hours before RNA was collect by TRIzol. Results showed 
that TLR3-inhibitor treatment caused a drop in IFN-β transcripts; from 33.9-fold to 22.4-
fold (p = 0.049) at 24 hours and 115.4-fold to 44.8-fold (p = 0.002) at 48 hours post 
infection (Figure 17a and d). Similarly, IDO transcripts were lower in the TLR3-inhibitor 
treatment group, 2.8-fold (DMSO: 10.2-fold, p < 0.0001) at 24 hours and 6.8 (DMSO: 
14.7-fold, p < 0.0001) at 48 hours (Figure 17c and f). As an IFN-β-inducible gene, TLR3 
expression was also affected later in the infection. At 24 hours the TLR3-inhibitor group 
was similar to the vehicle-treated cells, 20.5-fold and 22.1-fold respectively (p = 0.97). 
However, at 48 hours the vehicle group increased expression of TLR3 to 49.0-fold while 
the TLR3-inhibitor treatment remained at 21.0-fold (p = 0.002) (Figure 17b and e).
These results, and those presented previously, show a plausible pathway 
connecting the detection of RSV products by PRRs, the production of virus-stimulated 
genes, and the regulation of immune cell proliferation.
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Figure 14. IFN-β antagonism reduces RSV-induced IDO expression and activity
Incubation of infected cells with a neutralizing antibody against IFN-β was able to 
reduce IDO expression, protein, and activity (A, B, and C) without any effect on IFN-β 
transcript levels (D) or plaque-forming units in the supernatant (E). Significance 
determined by one-way ANOVA with Fisher’s LSD test. Error bars represent SEM, n = 
3. *** p < 0.001 **** p < 0.0001
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Figure 15. Endosomal TLR- and not RIG-I-pathway-inhibitors block IFN-β 
induction and IDO expression in RSV-infected MSCs
Infected MSCs treated with the endosomal TLR-pathway inhibitor chloroquine 
expressed lower levels of IDO and IFN-β versus non-treated cells while the RIG-I 
inhibitor BX795 had no effect (A, B). IDO protein and enzymatic activity measured from 
cell lysates were reduced in cells treated with chloroquine but not BX795 (C, D) despite 
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non-significant differences in RSV PFU production (E). Significance between groups 
determined by one-way ANOVA with Fisher’s LSD test. Error bars represent SEM, n = 
3. ** p < 0.01, *** p < 0.001, **** p < 0.0001
64
A. B.
Ve
hic
le
OD
N
20
88
0
20
40
60
80
Fo
ld
ex
pr
es
si
on
IFNb
Ve
hic
le
OD
N
20
88
0
20
40
60
80
Fo
ld
ex
pr
es
si
on
IDO
C. D.
Ve
hic
le
OD
N
20
88
0
10
20
30
Fo
ld
ex
pr
es
si
on
TLR3
Ve
hic
le
OD
N
20
88
0
1
2
3
4
5
6
7
8
Fo
ld
ex
pr
es
si
on
(lo
g)
RSVN
Mock RSV
Figure 16. The TLR7/8/9 antagonist inhibitory ODN 2088 has no effect on RSV-
stimulation of IFN-β, IDO, or TLR3
MSCs infected for 72 hours showed no significant changes response to ODN 
2088 treatment in respect to IFN-β (A), IDO (B), or TLR3 (C) expression. RSV infection, 
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measured by RSVN transcripts, was unaffected by the TLR7/8/9 inhibitor. Expression 
normalized to mock-infected vehicle control; Statistical significance determined by 2-
way ANOVA; n = 3.
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Figure 17. Antagonizing the TLR3-signaling pathway reduces IFN-β, IDO and 
TLR3 in RSV infected MSCs
Infected MSCs treated with the TLR3/dsRNA complex inhibitor expressed lower 
levels of IFN-β (A,D) and IDO (C,F) transcripts at 24 and 48 hours post infection 
compared with vehicle-treated cells. At 24 hours the expression of TLR3 was not 
different (B) however while vehicle-treated cells increased TLR3 expression by 48 hours 
the inhibitor-treated cells did not increase expression (E). Expression normalized to 
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mock-infected DMSO control; Statistical analysis by 2-way ANOVA; n = 3. * p < 0.05, ** 
p < 0.01, *** p < 0.001, **** p < 0.0001
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Chapter 7: Evaluation of the in vivo mouse model of RSV infection for 
investigating the role of MSCs and IDO
7.1 Introduction
Animal models are particularly important in the development of RSV vaccines 
and therapeutic treatments; especially in light of the failed formalin-inactivated vaccine 
of the 1960s [164], a disastrous clinical trial that still overshadows the field of RSV 
vaccine development to this day. It was not until decades later when a cotton rat model 
was able to reproduce the vaccine-enhanced disease that the mechanism behind the 
failed trial could be explored [165, 166].
RSV studies have been done in chimpanzees [167], rhesus monkey [167], 
African green monkey [168], and other primates [169], however use of these animals is 
typically limited due to funding and ethical concerns, and costs may result in difficulties 
obtaining sample sizes large enough to gain statistical significance [170]. Additionally, 
justification for the use of these animals is problematic due to the cheaper and less 
ethically frowned on animal models available. The ovine model, for example, has been. 
Cotton rat [171] and inbred mouse [172] are the two most published animal models of 
RSV infection, with mouse being the most used in the field. The cotton rat is more 
susceptible to RSV infection, taking a hundred-fold lower dose to cause disease than 
mouse, and responds with a antibody titers that are reported to be 10-fold or more 
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higher [172, 173]. However, drawbacks to the model include a lack of reagents such as 
monoclonal antibodies compared to mice. Additionally, the mouse model can make use 
of a vast library of inbred knockout and transgenic strains that are unavailable in any 
other animal model. In addition to the genetics and reagents other advantages include 
the relative ease compared to other animals of housing and maintaining the number of 
mice needed for a statistically sound study; the size per subject allowing for lower cost 
of drug and vaccine candidates; and mice have been shown to be permissive to the 
virus [172], although not so permissive as cotton rats.
The ultimate goal of the following work was to utilize an in vivo model to 
investigate the consequences of MSC infection with RSV. The mouse model was 
chosen and evaluated based on the lab’s experience utilizing the mouse in RSV 
research in addition to the considerations listed above. The results of these experiments 
showed that we could reproduce the findings reported by Rezaee et al. in 2011 [76]. 
However, we also revealed differences in the response of human and murine MSCs to 
infection with RSV in regards to IDO versus iNOS expression.
7.2 RSV infects and replicates in mouse MSCs
Mouse MSCs were grown out from bone marrow cultures and tested for MSC 
markers CD105, CD29, and Sca-1 and negative for the CD45 surface markers (Mouse 
Mesenchymal Stem Cell Multi-Color Flow Kit, R&D Systems, Minneapolis, MN) as 
described previously [174]. Early passage MSCs were infected at 1 MOI for 72 hours 
before imaging with a fluorescent microscope. mKate2-expression was used as an 
indicator of RSV infection. To confirm this result infected MSCs were grown on 
coverslips and stained for with an anti-RSV antibody conjugated to FITC, as previously 
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described. Results showed that mouse MSCs, like human MSCs, are capable of being 
infected by RSV (Figure 18).
7.3 RSV transcripts detected in bone marrow cells of infected animals
After ensuring mouse MSCs could be infected in vitro with human RSV we infected 
wild type Balb/c mice with 2 million PFUs of RSV intranasally. After 5 days of infection the 
lungs were isolated for immunohistochemistry using the previously described method. 
Sections of mouse lung were prepared by fixing and embedding the lung in OCT media prior 
to sectioning in a cryomicrotome and staining the sections with a polyclonal goat anti-RSV 
antibody. RSV in the lung was detected by a donkey anti-goat secondary antibody 
conjugated to Alex Fluor 555 (Figure 19a). In addition to the lung, bone marrow was flushed 
from the long bones of the hind legs and used for RNA and PFU assay. After isolation by 
TRIzol method RNA from the bone marrow cells was examined for RSV gene expression by 
RTqPCR. Results showed a low level of RSVN detected in the infected animals (Figure 
19b). However, no PFUs were detectable in any of the bone marrow aspirates. These 
results were reproducible through several experiments. These results indicated that, like 
fresh human bone marrow isolates, RSVN transcripts can be detected in mouse marrow 
following infection. However, no infective virions were detected in the bone in any of our 
experiments. This indicates that either there is too low a number of RSV virions a PFU 
assay or the infection of the mouse bone marrow is nonproductive.
7.4 RSV infection in IDO-deficient mice
To examine the effects of IDO on the infection in an in vivo model we utilized an 
IDO-knockout strain, B6.129-Ido1tm1Alm/J. Mice were infected with 3 million PFUs of RSV 
intranasally for 5 days before euthanasia and collection of lungs for 
71
immunohistochemistry, RNA, and PFU assay. Lungs for immunohistochemistry were 
fixed, cryopreserved, embedded in OCT, and sectioned as described previously. These 
sections were stained for RSV infection using a goat anti-RSV polyclonal primary 
antibody and a secondary anti-goat antibody labeled with Alexa Fluor 555. After 
mounting with anti-fade medium containing DAPI the sections were imaged using a 
fluorescent microscope. There was no difference in the amount of RSV staining, 
measured by red fluorescence, in the IDO-deficient mice versus wild type (Figure 20a). 
Further, RSVN expression (Figure 20b) and PFUs collected from the lung (Figure 20c) 
were not significantly different between the two strains of mice. There was also no 
statistically significant difference in IFN-β expression between the IDO-deficient strain 
and the wild type mice (Figure 20d). Interstingly, IDO was induced following RSV 
infection in the wild type mice to 146.8-fold the mock levels (p = 0.004, Figure 20e).
7.5 RSV infection of mouse MSCs induces iNOS and not IDO
After the previous result we wanted to determine whether the mouse presented 
an appropriate model for examination of IDO expression by MSCs in response to RSV 
infection. Therefore, wild type mouse bone marrow-derived MSCs, collected from the 
bones of the hind legs of mice, were grown for 3 passages before infection with RSV. 
72 hours post infection RNA was isolated and examined for IDO expression as well as 
IFN-β and inducible nitric oxide synthase (iNOS). Results showed that RSV induced 
128.2-fold increase of IFN-β transcripts (p = 0.0029), however IDO expression was 
unchanged (p = 0.23, Figure 21a and b). Interestingly, iNOS was highly transcribed 
following RSV infection at 594.1-fold the mock level (p = 0.0015, Figure 21c).
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These results stand in contrast to what has been reported above in human MSCs 
(Figure 8) and suggest that RSV infection in mice, both in vitro and in vivo, may be an 
unsuitable model for examining the role of MSCs in RSV infections, at least as it 
pertains to IDO activity.
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Figure 18. RSV infection of mouse MSCs
Mouse bone marrow-derived MSCs isolated from transgenic mice expressing 
GFP (C57BL/6-Tg(CAG-EGFP)131Osb/Ley SOPJ, Jackson Labs) were infected with 
RSV expression the fluorescent molecule mKate2 (red). After 72 hours fluorescent 
micrographs were captured to confirm the infection (A). RSV-infected wild type C57BL/6 
MSCs stained with the anti-RSV-FITC antibody confirmed the results (B).
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Figure 19. RSV transcripts in bone marrow of RSV infected mice
Lungs of mice infected with RSV were fixed in 4%PFA overnight, then 
cryopreserved in sucrose solution before embedding in OCT media. 5μm sections were 
stained with a primary goat polyclonal antibody against RSV and a secondary donkey 
anti-goat antibody conjugated to Alexa Fluor 555 (red). Stained sections were mounted 
with anti-fade and DAPI (blue) for imaging with a fluorescent microscope (A). H&E 
staining for lung structure was also performed (mock top panel, RSV bottom). RSVN 
transcript was detected in bone marrow aspirates (n = 4 mice) (B). ** p < 0.01 vs. mock
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Figure 20. IDO-KO mice infected with RSV have similar infection as wild type mice
RSV infected mice showed similar anti-RSV staining regardless of genetic 
background (A). Quantification of RSV transcript from total lung RNA (B) and PFUs from 
homogenized tissue (C) did not show any difference between wild type and IDO-
WT Mock WT RSV IDO-KO RSV
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deficient mice. IFN-β expression was similarly stimulated in both wild type and knockout 
mice (D), however only wildtype showed increased IDO in response to RSV infection 
(E). ** p < 0.01, *** p < 0.001 vs mock
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Figure 21. Mouse MSCs express iNOS but not IDO in response to RSV infection
RSV-infected mouse MSCs expressed high levels of IFN-β 72 hours following 
infection (A). IDO transcripts were not significantly different between the mock and 
infected groups at 72 hours (B). Infected MSCs did have high levels of iNOS mRNA (C) 
and RSVN expression confirmed infection (D). Results typical of repeated experiments 
in bone-derived mouse MSCs. Significance determined using Students T test 
comparing mock and infection, n = 3. ** p < 0.01
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Chapter 8: Conclusions
To date most RSV research has focused on the viral modulation of innate 
immune signaling within immortalized epithelial cell lines such as HEp-2 and A549 
although recent reports of RSV infecting and replicating in cells of the immune system 
including blood and lung neutrophils [73-75, 175], macrophages [98-100], and dendritic 
cells [70, 176, 177] suggest that RSV is capable of infecting cells of non-epithelial origin. 
Though extrapulmonary RSV infection of MSCs in humans was reported [76, 178], little 
is known about its role in virus-mediated immune regulation and the lack of protective 
immunity on subsequent secondary RSV infection. Our study addressed the role of 
MSCs as a target cell for RSV and the consequences of this extra-epithelial infection 
and is the first to report an increase in the expression of the immune regulatory factors 
IFN-β and IDO.
Our findings demonstrate that RSV infects MSCs in vitro and infective virus 
progeny are produced by the MSCs. This observation is similar to the other reports [76, 
178]. Infection of MSCs would require the virus to infect beyond the apical epithelial 
layer of the airway, a phenomenon that has been demonstrated in ovine and baboon 
animal models [169, 179]. In vitro air-liquid culturing of NHBE cells has allowed 
researchers to examine this further, demonstrating that RSV can gain access to and 
infect the basal progenitor cells beneath by epithelial denuding or physical damage to 
the apical cells [38, 180]. Similar mechanisms may permit RSV to gain access to airway 
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stromal cells such as MSCs. While scarce, tissues of infants and adults who have 
succumbed to severe RSV could go long way in determining whether the virus truly 
infects MSCs during the course of the disease. In one of the few studies of autopsy 
tissues RSV antigens were found throughout the lung but were most concentrated in 
areas where the airway epithelium was exfoliated [181], which in theory would provide 
access for the virus to sub-epithelial cell types like stromal cells.
We sought to identify factors that could be important in mediating the effects of 
RSV in MSCs by examining differential expression of chemokines and cytokines 
involved in the inflammatory response. Unlike with RSV-infected NHBE cells, RSV-
infected MSCs showed no change in the mRNA of the proinflammatory cytokines IL-6 or 
SDF-1 (CXCL12). However, there was a significant increase in the expression of the 
chemokine IL-8 (CXCL8), which is known for neutrophil recruitment and may be 
involved in mediating the inflammation and neutrophilia associated with severe RSV 
infections. Also, since neutrophils are susceptible to RSV [73] and are known to return 
to the bone marrow upon senescence [182, 183] they may contribute to the 
extrapulmonary RSV infection of bone MSCs observed by others [76, 178].
A major finding from our study relates to modulation of interferon expression and 
signaling by RSV-infected MSCs. Our results showed that when infected with RSV both 
NHBE and MSCs displayed significant upregulation of IFN-β, but not in IFN-γ or IFN-α. 
The functional relevance of this finding is unclear as RSV continues to replicate in 
MSCs and blocking IFN-β signaling with a neutralizing antibody did not increase or 
decrease virus replication. It is possible that RSV-induced IFN-β-signaling simply may 
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not be protective and/or represent a “high jacked” immune regulatory pathway in the 
case of RSV infection of MSCs.
Regulation of immunity by MSCs has been linked to active TLR signaling [184-
189] and products of RSV replication are known TLR ligands [44, 190, 191]. The results 
of our study showed chloroquine treatment of infected MSCs was sufficient to block 
IFN-β expression, which suggests that endosomal TLR recognition of viral products 
plays a key role in the MSC response to RSV infection. These results are similar to 
those reported for adenovirus and baculovirus, which induce an increased expression 
and TLR signaling in MSCs as well as increased IFN-β production [192]. Since RSV 
also stimulates immunity via the RNA helicase RIG-I through activation of the 
mitochondrial antiviral signaling complex (MAVS), TBK-1/IKKε, and IRF3 [193, 194], the 
role of this pathway in RSV infected MSCs was examined. Our results that the 
TBK1/IKKε inhibitor BX795 did not affect RSV-stimulated IFN-β expression suggest that 
the RIG-I pathway is not involved in this aspect of the MSC response to the virus.
Another major finding from our studies is that although MSCs produce a number 
of immune regulatory factors including iNOS, IL-1Ra, and PGE2 [86, 88, 195, 196], none 
of these were altered in their expression during RSV infection. However, RSV-infected 
MSCs did show a significant increase in IDO transcripts and protein, as well as activity 
of the enzyme. Further, RSV-infected MSCs exerted a greater inhibition of mitogen-
stimulated proliferation of human PBMCs through IDO activity. Antagonizing IDO activity 
with a competitive inhibitor such as 1-MT or vitamin K3 [95] reduced kynurenine levels in 
conditioned media of RSV infected MSCs and reversed the suppressive effect of MSC 
CM on lymphocyte proliferation, although these inhibitors did not affect RSV infective 
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rate or proliferation in MSCs. In agreement with this, bone marrow cells isolated from 
IDO deficient mice were infected by RSV equally as the wild type mice. These results 
suggest that the use of an IDO inhibitor during respiratory viral infection could result in a 
boosted immune response. This idea is consistent with a report which demonstrated 
that pretreatment of influenza-infected mice with 1-MT, increased inflammatory markers, 
such as IL-6, TNF-α and IFN-β [139], and Th1 cell numbers and boosted the secondary 
immune response [140]. 
In the report presented we found that blocking IFN-β signaling with a neutralizing 
antibody resulted in reduced IDO expression and enzymatic activity in infected MSCs. 
This conclusion agrees with reports in other immune cells showing an IFN-γ-
independent pathway in the production of IDO involving IFN-β [154, 155]. In contrast to 
IFN-γ-stimulated IDO, which plays the role of the canonical enzyme in the catabolism of 
tryptophan, IFN-β-induced IDO acts as a signaling molecule; recruiting Src homology 
region 2 domain-containing phosphatase (SHP)-1 and SHP-2, leading to noncanonical 
NF-κB pathway activation with RelB/p52, and promoting IFN-β and TGF-β production in 
a positive feedback loop leading to increased IDO and immune regulation [157, 197-
199]. In this study treatment of mouse DCs with TGF-β induced an increase in IDO and 
a tolerogenic profile that was not due to tryptophan degradation or kyneurinine 
production. The authors demonstrated that TGF-β-associated tolerogenic effects in 
pDCs [200] were prevented by IDO gene silencing, but not by the use of 1-MT, an 
inhibitor of IDO enzyme activity [201]. Further, they discovered that IDO contains two 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that, when phosphorylated, 
lead to the binding of either SOCS3 and eventual ubiquitin-mediated proteasomal 
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degradation [202] or the tyrosine phosphatases SHP-1 and SHP-2 which leads to non-
canonical NF-κB activation and a positive feedback loop involving expression of IFN-β 
and IDO [201] leading to the formation of long-term tolerogenic DCs [200]. While IDO 
enzymatic activity was shown in our work to play an important role in the regulation of 
PBMC activation this alternative pathway could also be involved, however this was not 
investigated during this study. In lieu of the knockout animal model, about which the 
work presented here has raised questions, a future study could utilize the 
CRISPR/Cas9 knockout technique in human MSCs to investigate whether removing the 
gene recapitulates the results found here. Additionally, investigation of the interaction of 
the SHP tyrosine phosphatases with IDO could unveil whether this non-enzymatic 
mechanism of IDO activity is involved or not during RSV infection of human MSCs.
The results of the PRR-pathway inhibitors demonstrated that chloroquine, the 
endosomal TLR inhibitor, but not BX795, the RIG-I pathway inhibitor, could reduce the 
RSV-stimulated IFN-β and IDO expression in MSCs. Further, upon interrogation of the 
endosomal TLRs with either inhibitory ODN 2088, a TLR7/8/9 antagonist, or 
TLR3/dsRNA complex inhibitor we found that TLR3 but not TLR7/8/9 play a role in this 
response to RSV in MSCs. These results together with the IFN-β neutralization study 
demonstrate a role for TLR3-stimulated IFN-β in the induction of IDO in MSCs. It is 
possible this IFN-β-dependent pathway is also active in other cell types during RSV 
infection, such as macrophages and apical cells of the airway epithelium, which also 
play a role in regulation of the immune system and could be a target for blocking 
immune regulation by IDO during viral infection.
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Our findings with MSCs differ from a recent report on IDO expression in which 
monocyte-derived dendritic cells (moDCs) were infected with recombinant green RSV 
[72]. This study indicated that the induction of IDO and IFN-γ were due to RIG-I pathway 
activity and not endosomal TLRs. Interestingly, in contrast to moDCs the RSV-infected 
MSCs used in the work presented here showed an increase in IFN-β, not in IFN-γ, and 
similar findings were shown with NHBE cells. This result is similar to those previously 
reported in other epithelial cell lines where RSV has been found to antagonize IFN-γ 
expression by inhibition of RIG-I pathway molecules via RSV nonstructural proteins [38, 
40]. These discrepancies suggest that the cell types used in each study may differ in 
their activation of molecular pattern recognition receptors and subsequent signaling, 
perhaps due to their differential susceptibility to RSV. The convergence of both cellular 
response pathways in the induction of IDO is an interesting finding, regardless. Future 
work could focus on the different viral response pathways triggered by classical antigen 
presenting cells such as monocytes and DCs compared to non-classical immune 
regulators like epithelial and stromal cells.
When translating these in vitro findings to the animal model we encountered 
some issues. The results gathered from IDO-knockout mouse experiments found no 
difference in the number of RSV PFU in the lungs of IDO-knockout versus wild type 
C57Bl/6 mice. One possible reason could be the reported disparity between mice and 
men in the immune-regulatory role of IDO. For example, in humans IDO has been 
shown to be induced in listeriosis and tuberculosis, however murine models of each of 
these diseases suggest that iNOS and not IDO is induced in mice [203]. In line with this, 
other reports have suggested that activated murine MSCs utilize iNOS in their immune 
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regulatory function, while human MSCs exert their effects via IDO under the same 
stimuli [204, 205]. Our findings using wild type mouse MSCs infected with RSV agree 
with these studies. We found no IDO expression following RSV infection of mouse 
MSCs and instead showed the induction of iNOS, a gene that was not expressed in 
human MSCs following RSV infection. Recently a group reported the use of a 
humanized mouse MSC model in which MSCs produced IDO under the control of the 
iNOS promoter [206]. Given these results showing the importance of MSCs in RSV 
pathogenesis and anti-RSV immunity a similar strategy may be useful to further 
elucidate the importance of IDO produced by RSV-infected MSCs. It is possible that this 
difference in IDO versus iNOS expression by stromal cells may play a role in the 
dissimilarities seen in RSV replication and response between mice and humans and 
also may account for the inability of the murine model of RSV infection to fully 
recapitulate the human disease [207-209]. Additionally, different strains of mouse have 
been found to be more or less permissive [172], and it is possible that strain variation in 
MSC expression of IDO, which has also been reported [210], may play a role in this 
variation in RSV permissiveness. The fact that MSCs from Balb/c, an 
immunocompromised mouse strain often utilized in the study of RSV, express more IDO 
than C57BL/6 could indicate that they are a better strain for the in vivo investigation of 
the role of MSCs in RSV infection. A future study could investigate whether IDO 
expression correlates with RSV permissiveness in mice and other animal models such 
as the cotton rat. Additionally, one could conceive of a murine model involving 
transgenic over-expression of IDO in the lung in order to increase mouse susceptibility 
to RSV and create a more similar disease at a lower infective dose.
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In summary, these results provide the first report that RSV infection of human 
bronchial epithelial cells and MSCs results in expression of the immune regulatory 
molecule IDO, which may be involved in disrupting the development of protective 
immunity against subsequent infections with the virus. Inhibition of virus-induced IDO 
production or activity may be a viable target for developing more effective therapies to 
respiratory viral pathogens. These results have implications beyond RSV-induced lung 
diseases, since the use of MSCs is being investigated in several areas of medicine 
including reducing rejection rates in solid organ transplantation, as cell-based therapy 
for autoimmune disease, as well as use in regenerative medicine [86-88, 196, 211]. A 
database search at ClinicalTrials.gov for the terms “Mesenchymal Stem Cells” returned 
304 open studies demonstrating the high level of interest in the use of these cells in a 
clinical setting. This underscores the importance of understanding the mechanisms of 
viral enhancement of their immune regulatory function, which may lead to procedures 
that optimize this feature for regulatory or regenerative applications.
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